{
  "$schema": "folio-library-document/v1",
  "id": "10665-273155",
  "title": "HIV diagnosis and ARV use in HIV-exposed infants: a programmatic update",
  "variant": "pdf",
  "pages": 24,
  "tocSource": "undetermined",
  "tocMethod": "font",
  "toc": [],
  "sections": [
    {
      "id": "page-001",
      "number": null,
      "title": "Page 1",
      "level": 1,
      "pageStart": 1,
      "pageEnd": 1,
      "labelStart": null,
      "labelEnd": null,
      "words": 15,
      "summary": {
        "text": "The cover page of the July 2018 WHO technical report on HIV diagnosis and ARV use in HIV-exposed infants, a programmatic update.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "HIV DIAGNOSIS AND ARV USE IN HIV-EXPOSED INFANTS: A PROGRAMMATIC UPDATE JULY 2018 TECHNICAL REPORT",
      "extractCut": false,
      "blocks": [
        "library/10665-273155/blocks/prose-page-001"
      ]
    },
    {
      "id": "page-002",
      "number": null,
      "title": "Page 2",
      "level": 1,
      "pageStart": 2,
      "pageEnd": 2,
      "labelStart": "2",
      "labelEnd": "2",
      "words": 487,
      "summary": {
        "text": "The copyright and cataloguing page, with the document number, Creative Commons licence terms, suggested citation and standard WHO disclaimers.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "creative commons",
          "heading": false
        },
        {
          "term": "suggested citation",
          "heading": false
        },
        {
          "term": "cds hiv",
          "heading": false
        },
        {
          "term": "licence",
          "heading": false
        },
        {
          "term": "igo",
          "heading": false
        },
        {
          "term": "health organization",
          "heading": false
        },
        {
          "term": "world health",
          "heading": false
        },
        {
          "term": "work",
          "heading": false
        }
      ],
      "extract": "WHO/CDS/HIV/18.17 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution- NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/ licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non- commercial purposes, provided the work is appropriately cited, as indicated",
      "extractCut": true,
      "blocks": [
        "library/10665-273155/blocks/prose-page-002"
      ]
    },
    {
      "id": "page-003",
      "number": null,
      "title": "Page 3",
      "level": 1,
      "pageStart": 3,
      "pageEnd": 3,
      "labelStart": "3",
      "labelEnd": "3",
      "words": 260,
      "summary": {
        "text": "Gives the executive summary, explaining that few countries have adopted the 2016 WHO innovations of birth testing, point-of-care NAT and enhanced postnatal prophylaxis, and that this update draws on 2017 and 2018 expert meetings to describe changing strategies for infant HIV. It is followed by a list of abbreviations.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "enhanced postnatal",
          "heading": false
        },
        {
          "term": "postnatal prophylaxis",
          "heading": false
        },
        {
          "term": "antiretroviral therapy",
          "heading": false
        },
        {
          "term": "nucleic acid",
          "heading": false
        },
        {
          "term": "mother-to-child transmission",
          "heading": false
        },
        {
          "term": "epnp",
          "heading": false
        },
        {
          "term": "nat",
          "heading": false
        },
        {
          "term": "infants",
          "heading": false
        }
      ],
      "extract": "1.1 EXECUTIVE SUMMARY New HIV infections in children continue to occur globally and timely diagnosis and treatment of infants and children living with HIV remain critically important. The 2016 WHO ARV Consolidated Guidelines presented some innovative approaches, such as the use of nucleic acid testing (NAT) at or around birth for earlier diagnosis of HIV in infants, the introduction of point-of-care (POC) NAT for",
      "extractCut": true,
      "blocks": [
        "library/10665-273155/blocks/prose-page-003"
      ]
    },
    {
      "id": "page-004",
      "number": null,
      "title": "Page 4",
      "level": 1,
      "pageStart": 4,
      "pageEnd": 4,
      "labelStart": "4",
      "labelEnd": "4",
      "words": 448,
      "summary": {
        "text": "Describes the status of paediatric HIV, noting the drop in new child infections under the Global Plan but 180 000 new infections in 2017, and the shift of mother-to-child transmission towards the postnatal period. A figure shows early and later transmission rates in the priority countries of the Start Free, Stay Free, AIDS Free framework.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "stay free",
          "heading": false
        },
        {
          "term": "hiv infections",
          "heading": false
        },
        {
          "term": "transmission dynamics",
          "heading": false
        },
        {
          "term": "pediatric hiv",
          "heading": false
        },
        {
          "term": "start free",
          "heading": false
        },
        {
          "term": "week transmission",
          "heading": false
        },
        {
          "term": "free framework",
          "heading": false
        },
        {
          "term": "transmission rate",
          "heading": false
        }
      ],
      "extract": "2.1 BACKGROUND 2.1.1 Current status quo regarding pediatric HIV The Global Plan Towards the Elimination of New HIV Infections among Children by 2015 and Keeping their Mothers Alive initiative has had a substantial impact, leading to a 60% reduction in new pediatric HIV infections in 21 high-burden countries in sub-Saharan Africa.1,2 Nevertheless, the burden of new HIV infections in children remains significant: in",
      "extractCut": true,
      "blocks": [
        "library/10665-273155/blocks/prose-page-004",
        "library/10665-273155/blocks/figure-vfig-p004"
      ]
    },
    {
      "id": "page-005",
      "number": null,
      "title": "Page 5",
      "level": 1,
      "pageStart": 5,
      "pageEnd": 5,
      "labelStart": "5",
      "labelEnd": "5",
      "words": 701,
      "summary": {
        "text": "Notes that only about half of children living with HIV were on treatment in 2017 and that untreated infants face very high mortality, then sets out the reasons for this technical update. It explains that falling transmission rates and low viremia have reduced the predictive value of nucleic acid tests, so false-positive infant diagnoses are increasingly reported. The page raises the question of introducing an indeterminate result range for early infant diagnosis.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "eid testing",
          "heading": false
        },
        {
          "term": "infants found",
          "heading": false
        },
        {
          "term": "epnp",
          "heading": false
        },
        {
          "term": "mtct rates",
          "heading": false
        },
        {
          "term": "false-positive test",
          "heading": false
        },
        {
          "term": "indeterminate range",
          "heading": false
        },
        {
          "term": "art initiation",
          "heading": false
        },
        {
          "term": "hiv infection",
          "heading": false
        }
      ],
      "extract": "Furthermore, although pediatric ART coverage has notably improved since 2010, only 51% of the estimated 1.8 million children living with HIV were receiving ART by the end of 2017.3 HIV-infected infants and younger children have an exceptionally high mortality without treatment, approximately 30% by the first year and 50% by their second year of life.9 Many HIV-related deaths in infants can be avoided by early",
      "extractCut": true,
      "blocks": [
        "library/10665-273155/blocks/prose-page-005"
      ]
    },
    {
      "id": "page-006",
      "number": null,
      "title": "Page 6",
      "level": 1,
      "pageStart": 6,
      "pageEnd": 6,
      "labelStart": "6",
      "labelEnd": "6",
      "words": 667,
      "summary": {
        "text": "Reports a systematic review indicating that a sizeable share of non-negative infant test results are indeterminate, most of which prove negative on retesting, and explains the use of PCR cycle thresholds to define an indeterminate range. It closes with definitions of terms such as indeterminate, non-negative and discordant results.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "indeterminate range",
          "heading": false
        },
        {
          "term": "confirmatory testing",
          "heading": false
        },
        {
          "term": "cycle threshold",
          "heading": false
        },
        {
          "term": "hiv-uninfected",
          "heading": false
        },
        {
          "term": "infants",
          "heading": false
        },
        {
          "term": "detectable",
          "heading": false
        },
        {
          "term": "hiv-infected",
          "heading": false
        },
        {
          "term": "pcr",
          "heading": false
        }
      ],
      "extract": "A systematic review of 32 studies using an indeterminate range found 14 753 non-negative test results of which 2 436 (16.5% [95% CI 15.9–17.1%]) were indeterminate (data unpublished); one study14 that reported the final diagnoses of indeterminate cases found that 76% of infants with an initial indeterminate test result were negative on repeat testing, suggesting these infants were not HIV-infected despite the",
      "extractCut": true,
      "blocks": [
        "library/10665-273155/blocks/prose-page-006",
        "library/10665-273155/blocks/figure-img-p006-1"
      ]
    },
    {
      "id": "page-007",
      "number": null,
      "title": "Page 7",
      "level": 1,
      "pageStart": 7,
      "pageEnd": 7,
      "labelStart": "7",
      "labelEnd": "7",
      "words": 793,
      "summary": {
        "text": "Discusses confirmatory testing, noting that prequalified point-of-care infant diagnosis devices perform comparably to laboratory tests and can be used to confirm positive results, and covers management of discordant results and treatment interruption. A summary box stresses immediate retesting of indeterminate results, team support for repeated cases and confirmatory testing of all positives.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "poc eid",
          "heading": false
        },
        {
          "term": "eid testing",
          "heading": false
        },
        {
          "term": "treatment interruption",
          "heading": false
        },
        {
          "term": "art interruption",
          "heading": false
        },
        {
          "term": "confirmatory testing",
          "heading": false
        },
        {
          "term": "eid technologies",
          "heading": false
        },
        {
          "term": "both eid",
          "heading": false
        },
        {
          "term": "hiv-infected infants",
          "heading": false
        }
      ],
      "extract": "period and all infants with a positive result receive a confirmatory test. Furthermore, those with repeatedly indeterminate test results should be actively tracked, retained, retested and their status resolved. Finally, POC EID testing is being implemented in several countries and settings (see 3.1.3). Previously there was limited evidence on how to conduct confirmatory testing of POC EID positive test results, but",
      "extractCut": true,
      "blocks": [
        "library/10665-273155/blocks/prose-page-007"
      ]
    },
    {
      "id": "page-008",
      "number": null,
      "title": "Page 8",
      "level": 1,
      "pageStart": 8,
      "pageEnd": 8,
      "labelStart": "8",
      "labelEnd": "8",
      "words": 719,
      "summary": {
        "text": "Covers the rollout of point-of-care early infant diagnosis, citing studies in Malawi and Mozambique showing faster results and earlier treatment, and lists lessons on device placement and site selection. It also addresses birth testing, and a box urges national regulators to approve the two prequalified technologies quickly.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "poc eid",
          "heading": false
        },
        {
          "term": "eid technologies",
          "heading": false
        },
        {
          "term": "adding nat",
          "heading": false
        },
        {
          "term": "birth testing",
          "heading": false
        },
        {
          "term": "art initiation",
          "heading": false
        },
        {
          "term": "hiv-infected infants",
          "heading": false
        },
        {
          "term": "penta immunization",
          "heading": false
        },
        {
          "term": "turnaround times",
          "heading": false
        }
      ],
      "extract": "3.1.3 Implementation of POC EID testing The 2016 WHO ARV Consolidated Guidelines10 recommend the use of NAT technologies for early infant HIV testing that have been developed and validated for use at or near the point-of-care. POC EID provides the opportunity to reduce test turnaround times, limit patient loss along the HIV testing cascade, reduce infant mortality and facilitate task shifting to lower cadres of",
      "extractCut": true,
      "blocks": [
        "library/10665-273155/blocks/prose-page-008"
      ]
    },
    {
      "id": "page-009",
      "number": null,
      "title": "Page 9",
      "level": 1,
      "pageStart": 9,
      "pageEnd": 9,
      "labelStart": "9",
      "labelEnd": "9",
      "words": 771,
      "summary": {
        "text": "Summarizes challenges of HIV testing at birth, such as staffing, sampling newborns and linkage to treatment, and describes country experiences in South Africa and Kenya. It stresses linking infected newborns to treatment with suitable formulations and the need for good leadership and coordination.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "birth pilot",
          "heading": false
        },
        {
          "term": "birth testing",
          "heading": false
        },
        {
          "term": "hiv-exposed newborns",
          "heading": false
        },
        {
          "term": "hiv-exposed infants",
          "heading": false
        },
        {
          "term": "hiv-infected infants",
          "heading": false
        },
        {
          "term": "pilot project",
          "heading": false
        },
        {
          "term": "test pilot",
          "heading": false
        },
        {
          "term": "nat",
          "heading": false
        }
      ],
      "extract": "• Birth testing is acceptable to mothers, but challenges arise from the increased human resources needed, the difficulty of collecting blood samples in newborns, the need to ensure sample collection outside of standard working hours and deliver results, linkage to ART and the nature of the EID system as a whole (stock-outs, referral mechanisms, delayed results). Box 4. Implementation of birth testing: country",
      "extractCut": true,
      "blocks": [
        "library/10665-273155/blocks/prose-page-009"
      ]
    },
    {
      "id": "page-010",
      "number": null,
      "title": "Page 10",
      "level": 1,
      "pageStart": 10,
      "pageEnd": 10,
      "labelStart": "10",
      "labelEnd": "10",
      "words": 5,
      "summary": {
        "text": "A blank page with no extractable text.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "_(no text on this page)_",
      "extractCut": false,
      "blocks": [
        "library/10665-273155/blocks/prose-page-010",
        "library/10665-273155/blocks/figure-img-p010-1"
      ]
    },
    {
      "id": "page-011",
      "number": null,
      "title": "Page 11",
      "level": 1,
      "pageStart": 11,
      "pageEnd": 11,
      "labelStart": "11",
      "labelEnd": "11",
      "words": 729,
      "summary": {
        "text": "Addresses interpretation of the 9-month infant test and simplification of the testing algorithm, explaining how maternal treatment, infant prophylaxis and late maternal infection can make rapid antibody tests unreliable for exposure or infection status. It sets out key points: testing mothers to establish exposure, not treating a negative infant result after 4 months as definitive, and confirming positive results with NAT.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "hiv-exposed infants",
          "heading": false
        },
        {
          "term": "hiv-infected infants",
          "heading": false
        },
        {
          "term": "exposure period",
          "heading": false
        },
        {
          "term": "rdt",
          "heading": false
        },
        {
          "term": "hiv exposure",
          "heading": false
        },
        {
          "term": "nat",
          "heading": false
        },
        {
          "term": "months old",
          "heading": false
        },
        {
          "term": "exposure status",
          "heading": false
        }
      ],
      "extract": "3.1.5 Ensuring accurate interpretation of the 9-month test and simplifying the testing algorithm The 2016 WHO ARV Consolidated Guidelines recommend that RDTs should be used to assess HIV exposure among infants younger than 4 months, while HIV exposure among infants 4–18 months old should be ascertained by testing the mother. When testing of the mother is not possible, current guidelines emphasize the importance of",
      "extractCut": true,
      "blocks": [
        "library/10665-273155/blocks/prose-page-011"
      ]
    },
    {
      "id": "page-012",
      "number": null,
      "title": "Page 12",
      "level": 1,
      "pageStart": 12,
      "pageEnd": 12,
      "labelStart": "12",
      "labelEnd": "12",
      "words": 879,
      "summary": {
        "text": "Explains the WHO recommendation of dual AZT and nevirapine prophylaxis for high-risk infants, extended to 12 weeks in breastfeeding infants, and defines which infants are high risk. It discusses the rationale based on mothers reaching viral suppression and gives guidance on whether to continue infant prophylaxis when maternal adherence is poor. It advises that prophylaxis, once stopped, should not be restarted and that attention should go to the causes of poor maternal adherence.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "adopted epnp",
          "heading": false
        },
        {
          "term": "infant prophylaxis",
          "heading": false
        },
        {
          "term": "breastfeeding infants",
          "heading": false
        },
        {
          "term": "continuing prophylaxis",
          "heading": false
        },
        {
          "term": "nvp alone",
          "heading": false
        },
        {
          "term": "breast milk",
          "heading": false
        },
        {
          "term": "plus nvp",
          "heading": false
        },
        {
          "term": "high-risk infants",
          "heading": false
        }
      ],
      "extract": "3.2. ARV use for prevention and treatment of HIV in infants 3.2.1 Implementation challenges to providing ePNP for high-risk infants The 2016 WHO ARV Consolidated Guidelines recommend a dual regimen of AZT and NVP which can be extended for up to 12 weeks in breastfeeding infants deemed to be at high risk of MTCT. A high-risk infant is defined as an infant whose mother was first identified as HIV-infected at delivery",
      "extractCut": true,
      "blocks": [
        "library/10665-273155/blocks/prose-page-012"
      ]
    },
    {
      "id": "page-013",
      "number": null,
      "title": "Page 13",
      "level": 1,
      "pageStart": 13,
      "pageEnd": 13,
      "labelStart": "13",
      "labelEnd": "13",
      "words": 725,
      "summary": {
        "text": "Considers giving high-risk infants presumptive triple-drug treatment as enhanced prophylaxis, paired with testing before it starts, and describes the limited and complex options for early infant treatment. It weighs the use of fixed-dose combination tablets, noting issues such as unwanted lamivudine exposure and the need to split tablets into quarters.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "pediatric fdc",
          "heading": false
        },
        {
          "term": "lpv pellets",
          "heading": false
        },
        {
          "term": "epnp",
          "heading": false
        },
        {
          "term": "infant prophylaxis",
          "heading": false
        },
        {
          "term": "nvp",
          "heading": false
        },
        {
          "term": "azt",
          "heading": false
        },
        {
          "term": "dose increases",
          "heading": false
        },
        {
          "term": "presumptive treatment",
          "heading": false
        }
      ],
      "extract": "As more effective treatments increasingly come to be used in pregnant women, we can expect decreasing MTCT rates. However, some women will still be diagnosed late or have incident infections and this group is likely to drive most new cases of HIV transmission to infants, owing to the high level of maternal virus in the absence of treatment. One possibility would be to provide “presumptive treatment” as postnatal",
      "extractCut": true,
      "blocks": [
        "library/10665-273155/blocks/prose-page-013"
      ]
    },
    {
      "id": "page-014",
      "number": null,
      "title": "Page 14",
      "level": 1,
      "pageStart": 14,
      "pageEnd": 14,
      "labelStart": "14",
      "labelEnd": "14",
      "words": 446,
      "summary": {
        "text": "Discusses integrating care for HIV-exposed infants into maternal and child health services and linked information systems, while noting pressure on staff. It also describes the role of community services and networks of women living with HIV, and lists patient-level and health system interventions to keep infants in the testing cascade.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "community-based services",
          "heading": false
        },
        {
          "term": "hiv services",
          "heading": false
        },
        {
          "term": "services play",
          "heading": false
        },
        {
          "term": "community engagement",
          "heading": false
        },
        {
          "term": "postnatal package",
          "heading": false
        },
        {
          "term": "service delivery",
          "heading": false
        },
        {
          "term": "pairs",
          "heading": false
        },
        {
          "term": "mch",
          "heading": false
        }
      ],
      "extract": "provide opportunities to strengthen service delivery for HIV-exposed infants. Integration within a well established maternal, neonatal, and child services platform, which traditionally provides services closest to clients, facilitates mother-infant pair follow-up and reduces the cost and time-visit burden on clients. The integrated information systems that link mother and infant information improve client tracking",
      "extractCut": true,
      "blocks": [
        "library/10665-273155/blocks/prose-page-014",
        "library/10665-273155/blocks/figure-img-p014-1"
      ]
    },
    {
      "id": "page-015",
      "number": null,
      "title": "Page 15",
      "level": 1,
      "pageStart": 15,
      "pageEnd": 15,
      "labelStart": "15",
      "labelEnd": "15",
      "words": 386,
      "summary": {
        "text": "Lists key research questions on infant diagnosis, prophylaxis and treatment, such as the value of birth testing and an indeterminate range and the dosing of new ARVs for newborns. A closing section calls for strengthening existing systems, tailoring strategies to context and gathering more programme evidence.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "infant prophylaxis",
          "heading": false
        },
        {
          "term": "cascade until",
          "heading": false
        },
        {
          "term": "birth testing",
          "heading": false
        },
        {
          "term": "until final",
          "heading": false
        },
        {
          "term": "epnp",
          "heading": false
        },
        {
          "term": "added value",
          "heading": false
        },
        {
          "term": "arvs",
          "heading": false
        },
        {
          "term": "eid",
          "heading": false
        }
      ],
      "extract": "Box 7: Key research questions Infant diagnosis • Assess the impact of implementing an indeterminate range, particularly at different testing time points, sample types, and technologies. • Acquire impact data to assess the added value of birth testing within the EID program. • Assess the value of providing birth testing to high-risk infants only. • Measure the impact of tracking tools (ie, bar codes) to ensure",
      "extractCut": true,
      "blocks": [
        "library/10665-273155/blocks/prose-page-015"
      ]
    },
    {
      "id": "page-016",
      "number": null,
      "title": "Page 16",
      "level": 1,
      "pageStart": 16,
      "pageEnd": 16,
      "labelStart": "16",
      "labelEnd": "16",
      "words": 172,
      "summary": {
        "text": "An acknowledgements page listing the meeting participants and their institutions and the WHO staff involved.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "chan school",
          "heading": false
        },
        {
          "term": "laura",
          "heading": false
        },
        {
          "term": "university",
          "heading": false
        },
        {
          "term": "moh",
          "heading": false
        },
        {
          "term": "harvard",
          "heading": false
        },
        {
          "term": "stellenbosch",
          "heading": false
        },
        {
          "term": "chai",
          "heading": false
        },
        {
          "term": "cdc",
          "heading": false
        }
      ],
      "extract": "ACKNOWLEDGEMENTS Meeting participants Adolfo Vubil (INS Mozambique), Ahmed Haeri Mazanderai (University of Pretoria), Andrea Ciaranello (Harvard Medical School), Angela Mushavi (MOH Zimbabwe), Anna Laura Ross (Unitaid), Archawin Rojanawiwat (Chulalongkorn University), Arne Kroidl (University of Munich), Charles Kiyaga (MOH Uganda), David Sullivan (USAID), Debbie Boras (London School of Hygiene and Tropical",
      "extractCut": true,
      "blocks": [
        "library/10665-273155/blocks/prose-page-016",
        "library/10665-273155/blocks/figure-img-p016-1"
      ]
    },
    {
      "id": "page-017",
      "number": null,
      "title": "Page 17",
      "level": 1,
      "pageStart": 17,
      "pageEnd": 17,
      "labelStart": "17",
      "labelEnd": "17",
      "words": 722,
      "summary": {
        "text": "Part of the reference list, citing studies on indeterminate PCR results, confirmatory and point-of-care infant testing in southern Africa, and related WHO documents.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "infant diagnosis",
          "heading": false
        },
        {
          "term": "south africa",
          "heading": false
        },
        {
          "term": "mazanderani",
          "heading": false
        },
        {
          "term": "hiv pcr",
          "heading": false
        },
        {
          "term": "sherman",
          "heading": false
        },
        {
          "term": "unaids",
          "heading": false
        },
        {
          "term": "hiv exposure",
          "heading": false
        },
        {
          "term": "hiv infection",
          "heading": false
        }
      ],
      "extract": "15. Mazanderani AH, Technau K-G, Hsiao N-Y, Maritz J, Carmona S, Sherman GG. Recommendations for the management of indeterminate HIV PCR results within South Africa’s early infant diagnosis programme. Southern African Journal of HIV Medicine. 2016;17(1):1-5. 16. Dunning L, Francke JA, Mallampati D, MacLean RL, Penazzato M, Hou T, et al. The value of confirmatory testing in early infant HIV diagnosis programmes in",
      "extractCut": true,
      "blocks": [
        "library/10665-273155/blocks/prose-page-017"
      ]
    },
    {
      "id": "page-018",
      "number": null,
      "title": "Page 18",
      "level": 1,
      "pageStart": 18,
      "pageEnd": 18,
      "labelStart": "18",
      "labelEnd": "18",
      "words": 140,
      "summary": {
        "text": "Annex 1, a standard operating procedure flowchart for managing indeterminate early infant diagnosis results, including retesting within 4 weeks and team review of repeated indeterminate results.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "eid sample",
          "heading": false
        },
        {
          "term": "current guidance",
          "heading": false
        },
        {
          "term": "indeterminate",
          "heading": false
        },
        {
          "term": "accordance",
          "heading": false
        },
        {
          "term": "manage",
          "heading": false
        }
      ],
      "extract": "EID sample no. 1 test no. 1 EID sample no. 1 test no. 2 NEGATIVE Manage in accordance with current guidance1 POSITIVE Manage in accordance with current guidance1 INDETERMINATE NEGATIVE Manage in accordance with current guidance1 POSITIVE Manage in accordance with current guidance1 INDETERMINATE2 Request a new sample within 4 weeks3,4 Further review by a clinical and laboratory team4 ANNEXES Annex 1: Managing",
      "extractCut": true,
      "blocks": [
        "library/10665-273155/blocks/prose-page-018"
      ]
    },
    {
      "id": "page-019",
      "number": null,
      "title": "Page 19",
      "level": 1,
      "pageStart": 19,
      "pageEnd": 19,
      "labelStart": "19",
      "labelEnd": "19",
      "words": 253,
      "summary": {
        "text": "Annex 2, a diagram for managing discordant results and treatment interruption, with infant NAT and viral load testing at 4 weeks, 4 months and 8 months after stopping ART and different scenarios depending on when breastfeeding ends.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "nat months",
          "heading": false
        },
        {
          "term": "nat weeks",
          "heading": false
        },
        {
          "term": "art interruption",
          "heading": false
        },
        {
          "term": "treatment interruption",
          "heading": false
        },
        {
          "term": "post art",
          "heading": false
        },
        {
          "term": "start art",
          "heading": false
        },
        {
          "term": "breastfeeding occurs",
          "heading": false
        },
        {
          "term": "stop art",
          "heading": false
        }
      ],
      "extract": "Annex 2: Managing discordant results and treatment interruption This option provides follow-up care to the infant for a minimum of 8 months after interruption of ART. Where possible, both EID (qualitative) and VL (quantitative) tests should be performed at 4 weeks, 4 months, and 8 months after treatment interruption. EID and viral load at 4 weeks, 4 months, and 8 months after interruption Scenario a: Cessation of",
      "extractCut": true,
      "blocks": [
        "library/10665-273155/blocks/prose-page-019"
      ]
    },
    {
      "id": "page-020",
      "number": null,
      "title": "Page 20",
      "level": 1,
      "pageStart": 20,
      "pageEnd": 20,
      "labelStart": "20",
      "labelEnd": "20",
      "words": 534,
      "summary": {
        "text": "Annex 3, a simplified algorithm for early infant HIV diagnosis from birth to 18 months, showing when to do NAT and antibody tests and when to start ART. It lists key principles such as testing the mother to assess exposure and doing NAT at 9 months, with notes on final diagnosis after breastfeeding ends.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "repeat nat",
          "heading": false
        },
        {
          "term": "perform nat",
          "heading": false
        },
        {
          "term": "previous nat",
          "heading": false
        },
        {
          "term": "antibody testing",
          "heading": false
        },
        {
          "term": "hiv-exposed infants",
          "heading": false
        },
        {
          "term": "infant child",
          "heading": false
        },
        {
          "term": "confirm infection",
          "heading": false
        },
        {
          "term": "start artc",
          "heading": false
        }
      ],
      "extract": "Annex 3: Simplified EID algorithm HIV-exposed newborn (0-2 days) Consider NATa,b Negative Negative Immediately start ARTc Repeat NAT to confirm infection Infant/child is infected HIV-exposed infant or child (4-6 weeks to 18 months) Conduct NATb (at 4-6 weeks or at the earliest opportunity thereafter) Positive Positive Immediately start ARTc Repeat NAT to confirm infection HIV infection not detected but if",
      "extractCut": true,
      "blocks": [
        "library/10665-273155/blocks/prose-page-020"
      ]
    },
    {
      "id": "page-021",
      "number": null,
      "title": "Page 21",
      "level": 1,
      "pageStart": 21,
      "pageEnd": 21,
      "labelStart": "21",
      "labelEnd": "21",
      "words": 227,
      "summary": {
        "text": "Annex 4, an algorithm for classifying infants as high or low risk at delivery based on the mother's HIV status, time on ART and viral load, to decide between standard and enhanced prophylaxis.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "hiv mother",
          "heading": false
        },
        {
          "term": "known hiv",
          "heading": false
        },
        {
          "term": "risk assessment",
          "heading": false
        },
        {
          "term": "art",
          "heading": false
        },
        {
          "term": "date",
          "heading": false
        },
        {
          "term": "weeks",
          "heading": false
        },
        {
          "term": "algorithm",
          "heading": false
        }
      ],
      "extract": "Annex 4: Algorithm for risk assessment This algorithm was developed to support risk assessment at the time of delivery and to help identify infants at high and low risk: Infants at low risk should be given standard prophylaxis (NVP or AZT alone for 4–6 weeks) while those at high risk should be given ePNP. In order to navigate this algorithm successfully, clinicians will need to know a number of parameters from the",
      "extractCut": true,
      "blocks": [
        "library/10665-273155/blocks/prose-page-021"
      ]
    },
    {
      "id": "page-022",
      "number": null,
      "title": "Page 22",
      "level": 1,
      "pageStart": 22,
      "pageEnd": 22,
      "labelStart": "22",
      "labelEnd": "22",
      "words": 433,
      "summary": {
        "text": "Annex 5, a table comparing syrup, tablet and fixed-dose combination options for AZT and nevirapine infant prophylaxis over 0–12 weeks, with doses and pros and cons of each. It notes that AZT has no separate prophylactic dose and that presumptive treatment should follow age-appropriate WHO dosing.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "nvp dose",
          "heading": false
        },
        {
          "term": "dose tab",
          "heading": false
        },
        {
          "term": "azt dose",
          "heading": false
        },
        {
          "term": "dose weeks",
          "heading": false
        },
        {
          "term": "plus nvp",
          "heading": false
        },
        {
          "term": "syrups",
          "heading": false
        },
        {
          "term": "twice",
          "heading": false
        },
        {
          "term": "fdc",
          "heading": false
        }
      ],
      "extract": "Annex 5: Dosing and formulation options for infant prophylaxis Dosage forms Dose 0-6 weeks AZT plus NVP Dose 6-12 weeks AZT plus NVP Dose 6-12 weeks NVP only Comments Syrups AZT 10mg/ml NVP 10mg/ml AZT dose 1.5ml (15mg) twice daily AZT dose 6ml (60mg) twice daily NVP dose 2ml (20mg) once daily - Accurate dosing for all drugs (included for low birth weight newborns) and one type of formulation for the whole 12-week",
      "extractCut": true,
      "blocks": [
        "library/10665-273155/blocks/prose-page-022"
      ]
    },
    {
      "id": "page-023",
      "number": null,
      "title": "Page 23",
      "level": 1,
      "pageStart": 23,
      "pageEnd": 23,
      "labelStart": "23",
      "labelEnd": "23",
      "words": 5,
      "summary": {
        "text": "A blank page with no extractable text.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "_(no text on this page)_",
      "extractCut": false,
      "blocks": [
        "library/10665-273155/blocks/prose-page-023",
        "library/10665-273155/blocks/figure-img-p023-1"
      ]
    },
    {
      "id": "page-024",
      "number": null,
      "title": "Page 24",
      "level": 1,
      "pageStart": 24,
      "pageEnd": 24,
      "labelStart": "24",
      "labelEnd": "24",
      "words": 21,
      "summary": {
        "text": "The back cover, giving contact details for the WHO Department of HIV/AIDS in Geneva and the document number.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "e-mail",
          "heading": false
        },
        {
          "term": "hiv-aids",
          "heading": false
        },
        {
          "term": "int",
          "heading": false
        }
      ],
      "extract": "For more information, contact: World Health Organization Department of HIV/AIDS 20, avenue Appia 1211 Geneva 27 Switzerland WHO/CDS/HIV/18.17 E-mail: hiv-aids@who.int www.who.int/hiv",
      "extractCut": false,
      "blocks": [
        "library/10665-273155/blocks/prose-page-024"
      ]
    }
  ],
  "checks": {
    "figureSequenceGaps": [],
    "pageLabelConflicts": {
      "count": 0,
      "items": []
    }
  },
  "withheld": false,
  "keywords": [
    {
      "term": "hiv-exposed infants",
      "heading": false
    },
    {
      "term": "infants testing",
      "heading": false
    },
    {
      "term": "breastfeeding infants",
      "heading": false
    },
    {
      "term": "hiv-infected infants",
      "heading": false
    },
    {
      "term": "nat weeks",
      "heading": false
    },
    {
      "term": "infant hiv",
      "heading": false
    },
    {
      "term": "nat months",
      "heading": false
    },
    {
      "term": "poc nat",
      "heading": false
    },
    {
      "term": "infant prophylaxis",
      "heading": false
    },
    {
      "term": "high-risk infants",
      "heading": false
    },
    {
      "term": "eid testing",
      "heading": false
    },
    {
      "term": "among infants",
      "heading": false
    }
  ],
  "pageLabels": [
    {
      "physical": 1,
      "label": null,
      "source": null,
      "confidence": 0
    },
    {
      "physical": 2,
      "label": "2",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 3,
      "label": "3",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 4,
      "label": "4",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 5,
      "label": "5",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 6,
      "label": "6",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 7,
      "label": "7",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 8,
      "label": "8",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 9,
      "label": "9",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 10,
      "label": "10",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 11,
      "label": "11",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 12,
      "label": "12",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 13,
      "label": "13",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 14,
      "label": "14",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 15,
      "label": "15",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 16,
      "label": "16",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 17,
      "label": "17",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 18,
      "label": "18",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 19,
      "label": "19",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 20,
      "label": "20",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 21,
      "label": "21",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 22,
      "label": "22",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 23,
      "label": "23",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 24,
      "label": "24",
      "source": "printed",
      "confidence": 0.7
    }
  ],
  "figures": [
    {
      "kind": "box",
      "number": "1",
      "title": "Definition of terms for diagnostic results",
      "page": 6,
      "pageLabel": "6",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "box",
      "number": "2",
      "title": "Prioritizing confirmatory testing of positive",
      "page": 7,
      "pageLabel": "7",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "box",
      "number": "3",
      "title": "New POC EID technologies",
      "page": 8,
      "pageLabel": "8",
      "confidence": 0.6,
      "evidence": [
        "in-sequence"
      ]
    },
    {
      "kind": "box",
      "number": "4",
      "title": "Implementation of birth testing:",
      "page": 9,
      "pageLabel": "9",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "box",
      "number": "5",
      "title": "Use of RDT: implementation considerations",
      "page": 11,
      "pageLabel": "11",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "box",
      "number": "6",
      "title": "ARV Formulations for ePNP: implementation",
      "page": 13,
      "pageLabel": "13",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "box",
      "number": "7",
      "title": "Key research questions Infant diagnosis",
      "page": 15,
      "pageLabel": "15",
      "confidence": 0.6,
      "evidence": [
        "in-sequence"
      ]
    }
  ],
  "images": [
    {
      "id": "vfig-p004",
      "file": "figures/vfig-p004.webp",
      "page": 4,
      "shows": [
        "Figure 1"
      ],
      "narratives": {
        "en": "Stacked horizontal bar chart of mother-to-child transmission (MTCT) rates in 2017 in the 22 Start Free, Stay Free, AIDS Free priority countries, split into 6-week transmission rate (dark blue) and post-6-week transmission rate (light blue), with totals at the bar ends; the render is cropped at the left and also includes body text above. Totals range from 26% in Indonesia, Angola and Nigeria to 5% in South Africa and Botswana; for example Indonesia 19% + 7%, Nigeria 14% + 14%, and Botswana 3% + 2%.",
        "ar": "مخطط شريطي أفقي مكدّس لمعدلات انتقال العدوى من الأم إلى الطفل في عام 2017 في البلدان الاثنين والعشرين ذات الأولوية ضمن إطار «البداية الحرة، والبقاء أحراراً، والتحرّر من الإيدز»، مقسّمة إلى معدل الانتقال حتى 6 أسابيع (أزرق داكن) ومعدل الانتقال بعد 6 أسابيع (أزرق فاتح)، مع المجاميع في نهاية الأشرطة؛ والصورة مقتطعة من اليسار وتتضمن أيضاً نصاً في الأعلى. تتراوح المجاميع بين 26% في إندونيسيا وأنغولا ونيجيريا و5% في جنوب أفريقيا وبوتسوانا؛ مثلاً إندونيسيا 19% + 7%، ونيجيريا 14% + 14%، وبوتسوانا 3% + 2%.",
        "zh": "堆积水平条形图，显示2017年“无艾起点、无艾成长、无艾生活”框架下22个重点国家的母婴传播率，分为6周传播率（深蓝色）和6周后传播率（浅蓝色），条形末端标有合计；渲染图左侧被裁切，上方还包含正文文字。合计从印度尼西亚、安哥拉和尼日利亚的26%到南非和博茨瓦纳的5%不等；例如印度尼西亚19%+7%，尼日利亚14%+14%，博茨瓦纳3%+2%。",
        "es": "Gráfico de barras horizontales apiladas de las tasas de transmisión maternoinfantil (TMI) en 2017 en los 22 países prioritarios del marco Start Free, Stay Free, AIDS Free, dividido en tasa de transmisión a las 6 semanas (azul oscuro) y tasa de transmisión posterior a las 6 semanas (azul claro), con los totales al final de las barras; la imagen está recortada a la izquierda e incluye también texto en la parte superior. Los totales van del 26% en Indonesia, Angola y Nigeria al 5% en Sudáfrica y Botswana; por ejemplo, Indonesia 19% + 7%, Nigeria 14% + 14% y Botswana 3% + 2%.",
        "fr": "Diagramme à barres horizontales empilées des taux de transmission mère-enfant (TME) en 2017 dans les 22 pays prioritaires du cadre Start Free, Stay Free, AIDS Free, répartis entre taux de transmission à 6 semaines (bleu foncé) et taux de transmission après 6 semaines (bleu clair), avec les totaux en bout de barre ; le rendu est rogné à gauche et inclut aussi du texte au-dessus. Les totaux vont de 26 % en Indonésie, en Angola et au Nigéria à 5 % en Afrique du Sud et au Botswana ; par exemple Indonésie 19 % + 7 %, Nigéria 14 % + 14 % et Botswana 3 % + 2 %.",
        "ru": "Горизонтальная столбчатая диаграмма с накоплением, показывающая показатели передачи ВИЧ от матери ребёнку (ПМР) в 2017 г. в 22 приоритетных странах рамочной программы «Start Free, Stay Free, AIDS Free» с разделением на показатель передачи к 6 неделям (тёмно-синий) и после 6 недель (светло-синий) и итогами в конце столбцов; изображение обрезано слева и включает также текст сверху. Итоговые значения — от 26% в Индонезии, Анголе и Нигерии до 5% в Южной Африке и Ботсване; например, Индонезия 19% + 7%, Нигерия 14% + 14%, Ботсвана 3% + 2%."
      },
      "state": "draft"
    },
    {
      "id": "img-p006-1",
      "file": "images/img-p006-1.webp",
      "page": 6,
      "narratives": {
        "en": "Photograph of a newborn baby swaddled in a white cloth, lying on a dark surface.",
        "ar": "صورة فوتوغرافية لمولود جديد ملفوف بقماش أبيض، مستلقٍ على سطح داكن.",
        "zh": "照片：一个用白布包裹的新生儿躺在深色的表面上。",
        "es": "Fotografía de un recién nacido envuelto en una tela blanca, acostado sobre una superficie oscura.",
        "fr": "Photographie d’un nouveau-né emmailloté dans un linge blanc, allongé sur une surface sombre.",
        "ru": "Фотография новорождённого, запелёнутого в белую ткань и лежащего на тёмной поверхности."
      },
      "state": "draft"
    },
    {
      "id": "img-p010-1",
      "file": "images/img-p010-1.webp",
      "page": 10,
      "narratives": {
        "en": "Photograph of a smiling infant in a yellow top leaning on the lap of an adult who is partly visible in the foreground.",
        "ar": "صورة فوتوغرافية لرضيع مبتسم يرتدي قميصاً أصفر ويستند إلى حِجر شخص بالغ يظهر جزئياً في المقدّمة.",
        "zh": "照片：一个身穿黄色上衣、面带笑容的婴儿趴在前景中部分可见的成人腿上。",
        "es": "Fotografía de un bebé sonriente con camiseta amarilla apoyado en el regazo de un adulto, parcialmente visible en primer plano.",
        "fr": "Photographie d’un nourrisson souriant en haut jaune, appuyé sur les genoux d’un adulte partiellement visible au premier plan.",
        "ru": "Фотография улыбающегося младенца в жёлтой кофточке, опирающегося на колени взрослого, частично видного на переднем плане."
      },
      "state": "draft"
    },
    {
      "id": "img-p014-1",
      "file": "images/img-p014-1.webp",
      "page": 14,
      "narratives": {
        "en": "Photograph of a health worker in gloves collecting blood spots from an infant's heel onto a sample card while a woman holds the baby.",
        "ar": "صورة فوتوغرافية لعامل صحي يرتدي قفازين ويجمع بقع دم من كعب رضيع على بطاقة عيّنات بينما تحمل امرأة الطفل.",
        "zh": "照片：一名戴手套的卫生工作者从婴儿足跟采集血斑到样本卡上，一名女子抱着婴儿。",
        "es": "Fotografía de un trabajador sanitario con guantes que recoge gotas de sangre del talón de un lactante en una tarjeta de muestra mientras una mujer sostiene al bebé.",
        "fr": "Photographie d’un agent de santé ganté recueillant des gouttes de sang au talon d’un nourrisson sur une carte de prélèvement, tandis qu’une femme tient le bébé.",
        "ru": "Фотография медицинского работника в перчатках, собирающего капли крови из пятки младенца на карточку для образцов, пока женщина держит ребёнка."
      },
      "state": "draft"
    },
    {
      "id": "img-p016-1",
      "file": "images/img-p016-1.webp",
      "page": 16,
      "narratives": {
        "en": "Photograph of several women in colourful clothing and head wraps holding or carrying infants at an outdoor gathering, with men standing behind.",
        "ar": "صورة فوتوغرافية لعدة نساء بملابس ملوّنة وأغطية رأس يحملن رضّعاً في تجمّع في الهواء الطلق، ويقف رجال خلفهن.",
        "zh": "照片：几名身穿彩色服装、头戴头巾的妇女在户外聚集处抱着或背着婴儿，后面站着几名男子。",
        "es": "Fotografía de varias mujeres con ropa colorida y pañuelos en la cabeza que sostienen o cargan bebés en una reunión al aire libre, con hombres de pie detrás.",
        "fr": "Photographie de plusieurs femmes en vêtements colorés et foulards portant des nourrissons lors d’un rassemblement en plein air, avec des hommes debout derrière elles.",
        "ru": "Фотография нескольких женщин в яркой одежде и головных повязках, держащих или несущих младенцев на собрании под открытым небом; позади стоят мужчины."
      },
      "state": "draft"
    },
    {
      "id": "img-p023-1",
      "file": "images/img-p023-1.webp",
      "page": 23,
      "narratives": {
        "en": "Photograph of an infant in a red top looking over the shoulder of a woman wearing an orange veil.",
        "ar": "صورة فوتوغرافية لرضيع يرتدي قميصاً أحمر وينظر من فوق كتف امرأة ترتدي وشاحاً برتقالياً.",
        "zh": "照片：一个身穿红色上衣的婴儿从一名戴橙色面纱的女子肩头向外看。",
        "es": "Fotografía de un bebé con camiseta roja que mira por encima del hombro de una mujer con un velo naranja.",
        "fr": "Photographie d’un nourrisson en haut rouge regardant par-dessus l’épaule d’une femme portant un voile orange.",
        "ru": "Фотография младенца в красной кофточке, выглядывающего из-за плеча женщины в оранжевом покрывале."
      },
      "state": "draft"
    }
  ],
  "coverage": [
    {
      "kind": "contents",
      "state": "not-extracted",
      "note": "split one section per page; no contents was trusted"
    },
    {
      "kind": "sections",
      "state": "partial",
      "count": 24,
      "note": "one per page, not by heading"
    },
    {
      "kind": "figures",
      "state": "found",
      "count": 6
    },
    {
      "kind": "tables",
      "state": "not-extracted"
    },
    {
      "kind": "references",
      "state": "not-extracted",
      "note": "a references section is in the text (p17); its entries are not extracted"
    },
    {
      "kind": "glossary",
      "state": "not-extracted",
      "note": "a glossary section is in the text (p3); its entries are not extracted"
    },
    {
      "kind": "footnotes",
      "state": "not-extracted"
    },
    {
      "kind": "summaries",
      "state": "found",
      "count": 24,
      "note": "24 of 24 sections"
    }
  ],
  "links": {
    "repo": "litlfred/who-iris",
    "branch": "main",
    "dir": "library/10665-273155"
  }
}
